tiprankstipranks

Privia Health Group’s Strong Performance and Strategic Expansion Drive Positive Outlook

Privia Health Group’s Strong Performance and Strategic Expansion Drive Positive Outlook

Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Privia Health Group (PRVAResearch Report), boosting the price target to $32.00.

Don’t Miss TipRanks’ Half-Year Sale

Whit Mayo’s rating is based on several compelling factors that highlight the strong performance and future potential of Privia Health Group. The company reported robust first-quarter results for 2025, surpassing market expectations across various metrics. This success is attributed to the significant growth in implemented providers and strong ambulatory utilization, which drove impressive top-line performance. Additionally, the company’s adjusted EBITDA exceeded street expectations by 14.5%, with a notable increase in margins.
Privia Health Group’s strategic expansion into the Arizona market through a partnership with Integrated Medical Services (IMS) further strengthens its position. This partnership, involving a high-performing multi-specialty practice, is expected to be EBITDA positive by the fourth quarter of 2025, faster than previous partnerships. The transaction underscores Privia’s ability to collaborate with larger practices and enhances confidence in its earnings growth trajectory. Consequently, Whit Mayo modestly raised the company’s estimates and price target, reflecting the positive outlook for continued growth and profitability.

Mayo covers the Healthcare sector, focusing on stocks such as Pediatrix Medical Group, Ardent Health Partners, Inc., and Humana. According to TipRanks, Mayo has an average return of 2.8% and a 49.37% success rate on recommended stocks.

In another report released on May 9, Evercore ISI also maintained a Buy rating on the stock with a $30.00 price target.

Disclaimer & DisclosureReport an Issue

1